MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $4.46 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 13.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 102,127 shares of the company's stock after acquiring an additional 12,084 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.06% of Revolution Medicines worth $4,463,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. Integral Health Asset Management LLC raised its holdings in Revolution Medicines by 57.1% in the 4th quarter. Integral Health Asset Management LLC now owns 550,000 shares of the company's stock worth $24,057,000 after acquiring an additional 200,000 shares during the period. J. Goldman & Co LP bought a new position in Revolution Medicines in the 4th quarter worth $1,152,000. Janus Henderson Group PLC raised its holdings in Revolution Medicines by 54.5% in the 4th quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company's stock worth $414,777,000 after acquiring an additional 3,346,755 shares during the period. Jefferies Financial Group Inc. bought a new position in Revolution Medicines in the 4th quarter worth $994,000. Finally, Ensign Peak Advisors Inc raised its holdings in Revolution Medicines by 667.1% in the 4th quarter. Ensign Peak Advisors Inc now owns 305,172 shares of the company's stock worth $13,348,000 after acquiring an additional 265,389 shares during the period. Institutional investors own 94.34% of the company's stock.

Wall Street Analyst Weigh In

RVMD has been the topic of several research analyst reports. Wedbush restated an "outperform" rating and issued a $67.00 price target on shares of Revolution Medicines in a research report on Thursday, May 8th. Stifel Nicolaus decreased their price target on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Guggenheim decreased their price target on shares of Revolution Medicines from $87.00 to $80.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Oppenheimer raised their price target on shares of Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Finally, Needham & Company LLC restated a "buy" rating and issued a $57.00 price target on shares of Revolution Medicines in a research report on Thursday, May 8th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $67.08.

Insider Activity

In other Revolution Medicines news, CFO Jack Anders sold 1,864 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $72,770.56. Following the transaction, the chief financial officer now directly owns 115,006 shares in the company, valued at $4,489,834.24. The trade was a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark A. Goldsmith sold 11,738 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $458,251.52. Following the completion of the transaction, the insider now owns 441,564 shares in the company, valued at approximately $17,238,658.56. This trade represents a 2.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,660 shares of company stock worth $650,406. Corporate insiders own 8.20% of the company's stock.

Revolution Medicines Price Performance

Shares of Revolution Medicines stock traded up $0.97 during trading on Friday, hitting $39.77. 1,398,581 shares of the company's stock traded hands, compared to its average volume of 1,494,173. The firm's fifty day moving average price is $37.55 and its 200 day moving average price is $42.55. Revolution Medicines, Inc. has a twelve month low of $29.17 and a twelve month high of $62.40. The company has a market cap of $7.41 billion, a PE ratio of -11.08 and a beta of 1.11.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same quarter last year, the business posted ($0.70) EPS. As a group, equities research analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.